Last reviewed · How we verify
STIMUFEND (PEGFILGRASTIM-FPGK)
STIMUFEND (generic name: PEGFILGRASTIM-FPGK) is a Leukocyte Growth Factor [EPC] drug developed by FRESENIUS KABI USA. It is currently FDA-approved.
At a glance
| Generic name | PEGFILGRASTIM-FPGK |
|---|---|
| Sponsor | FRESENIUS KABI USA |
| Drug class | Leukocyte Growth Factor [EPC] |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
- Bone pain
- Pain in extremity
Serious adverse events
- Splenic Rupture
- Acute Respiratory Distress Syndrome
- Serious Allergic Reactions
- Glomerulonephritis
- Leukocytosis
- Thrombocytopenia
- Use in Patients with Sickle Cell Disorders
Key clinical trials
- A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Addition of Bevacizumab (NSC-704865) in Three Cohorts of Patients With Inoperable Locally Advanced Stage I (Phase 2)
- Ruxolitinib in Combination With Chemotherapy for Untreated Nodal T-Follicular Helper (TFH) Cell Lymphomas (Phase 1)
- A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular &Amp; Spinal Canal Irradiation (WVSCI) for Patients With Localized Non-Germinomatous Central Nervous System Germ Cell Tumor (Phase 2)
- A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (Phase 3)
- A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas (Phase 1)
- Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) ± Rituximab + Recombinant Erwinia Asparaginase (JZP458; Rylaze®) for the Treatment of Newly-Diagnosed Adu (Phase 2)
- Phase II Study of Dose-Adjusted EPOCH ± Rituximab + Ponatinib for Adults With Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma (Phase 2)
- A Phase II/III Trial of Durvalumab and Chemotherapy for Patients With High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy (Phase 2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- STIMUFEND CI brief — competitive landscape report
- STIMUFEND updates RSS · CI watch RSS
- FRESENIUS KABI USA portfolio CI
Frequently asked questions about STIMUFEND
What is STIMUFEND?
STIMUFEND (PEGFILGRASTIM-FPGK) is a Leukocyte Growth Factor [EPC] drug developed by FRESENIUS KABI USA.
Who makes STIMUFEND?
STIMUFEND is developed and marketed by FRESENIUS KABI USA (see full FRESENIUS KABI USA pipeline at /company/fresenius-kabi-usa).
What is the generic name of STIMUFEND?
PEGFILGRASTIM-FPGK is the generic (nonproprietary) name of STIMUFEND.
What drug class is STIMUFEND in?
STIMUFEND belongs to the Leukocyte Growth Factor [EPC] class. See all Leukocyte Growth Factor [EPC] drugs at /class/leukocyte-growth-factor-epc.
What development phase is STIMUFEND in?
STIMUFEND is FDA-approved (marketed).
What are the side effects of STIMUFEND?
Common side effects of STIMUFEND include Bone pain, Pain in extremity. Serious adverse events: Splenic Rupture, Acute Respiratory Distress Syndrome, Serious Allergic Reactions, Glomerulonephritis.
Related
- Drug class: All Leukocyte Growth Factor [EPC] drugs
- Manufacturer: FRESENIUS KABI USA — full pipeline
- Therapeutic area: All drugs in Other